Privacy Analytics now part of IMS Health
We’d like to announce that IMS Health (NYSE: IMS) has acquired Privacy Analytics. IMS Health is a leading global information and technology services company providing clients in the healthcare industry...
View ArticleImproving Health IT Act Potential to Assist ‘Moon shot’
As the US prepares for the upcoming presidential election, Congress will not only break for summer in August but will also have an extended break in October and November. This means there will be fewer...
View ArticlePrivacy Analytics buy to help leverage IMS Health’s data
Health Data Management discusses the recent news that IMS Health has acquires Privacy Analytics. Their article discusses the acquisition briefly from the perspectives of John Osberg, a mergers and...
View ArticleData Privacy Checkup
Risk Management Magazine has published a recent article by Privacy Analytics’ Sam Wehbe. In Data Privacy Checkup, Wehbe discusses the challenge Privacy Officers face when establishing best practices...
View ArticleHealthcare struggles to protect privacy of PHI
SC Congress Toronto featured a panel with Privacy Analytics’ Pamela Buffone, Ann Cavoukian and Anita Fineberg entitled Managing Privacy and Risk When Sharing PHI. The panel was a discussion focusing on...
View ArticleThe Rising Demand for RWE
In light of our recent acquisition by IMS, Privacy Analytics’ value as the provider of de-identification and anonymization software and services has never been more vital than when you consider its...
View ArticlePrivacy Dimensions in Big Data
Khaled El Emam’s latest article for the IAPP’s Privacy Perspectives blog is now online. His article, Setting the record straight on privacy dimensions in big data, discusses how terminology can hinder...
View ArticleWhat IMS Health will do with Privacy Analytics — and vice versa
IAPP’s Sam Pfeifle discusses the IMS acquisition of Privacy Analytics in his article, What IMS Health will do with Privacy Analytics — and vice versa. “For our clients and the companies that we’re...
View ArticleThe Limitations on Learning from Clinical Trials
One of the many benefits from RWE can be realized when you look at the limitations on learning from clinical trials themselves. A randomized clinical trial (RCT) is still the current standard to...
View ArticleUsing RWE Across the Drug Product Lifecycle
In addition to providing insights about comparative effectiveness and pharmacovigilance, drug makers are being spurred to consider real world evidence (RWE) in a broader context. With the price tag for...
View ArticleClik here to view.
Building a De-identification Pipeline to Support RWE
To use patient-level data for RWE initiatives, biopharmaceutical companies must first obtain the patient’s consent that their data can be shared for secondary purposes; otherwise, they must de-identify...
View ArticleFinal Thoughts on RWE
The last few weeks we have been focusing on the benefits of Real World Evidence (RWE). In these final thoughts, wrapping up our series on RWE, we can’t emphasize the value of created a real world...
View ArticleStrengthening Secondary Use
How Registries Can Responsibly Share Data Data registries are an invaluable tool that require the secondary use of data for conducting evidence-based healthcare research. Concern for patient...
View ArticleUnlocking Big Data for Healthcare
There are powerful opportunities facing healthcare today. Big Data Analytics (BDA) is being leveraged by a broad spectrum of healthcare organizations to solve ongoing challenges. BDA is opening doors...
View ArticleThe First Step Towards Sharing Big Data
If you are planning on sharing health data for secondary purposes, the first step towards sharing Big Data is de-identification. As previous blog posts have shown, not all de-identification techniques...
View ArticleDe-identification Experts Wanted
Don’t share PHI without reading this Sharing health information for secondary purposes responsibly has become critical for many providers and healthcare organizations. This is why it is imperative that...
View ArticleSmart Cities Need a Privacy Policy
In Terry Dawes latest piece on Cantech Letter, he writes that as cities start implementing high tech solutions to solve modern problems, privacy may suffer without sufficient policies to protect it....
View ArticleThe Cure-All for 21st Century Data Sharing
PharmaExec just published Privacy Analytics’ Pamela Buffone’s article, The ‘Cure’-All for 21st Century Data Sharing. In her article, Buffone looks at the revised 21st Century Cures Act – a broach...
View ArticleOpen Data Should Be Responsible Data
A new editorial by the New England Journal of Medicine attracted a lot of attention earlier this month when a group of researchers argued that science is moving too hastily towards open data. The...
View ArticleBig Data and Healthcare
Implications for Use and Privacy Big Data and the Internet of Things have widespread implications not only for business models but individual privacy. Balancing the requirements of emerging business...
View Article